ERBB2 and neoplasm: This result can serve as evidence for the selectivity of the candidate TCR, as it shows that T cells expressing this TCR can preferably target tumor cells characterized by a 100–200-fold increase in HER2/neu receptor concentration [9] while sparing normal cells that have lower levels of HER2/neu receptors.